Article
 

Oncogenic KRAS promotes malignant brain tumors in zebrafish

Public Deposited

Contenu téléchargeable

Télécharger le fichier PDF
https://ir.library.oregonstate.edu/concern/articles/05741t517

Descriptions

Attribute NameValues
Creator
Abstract
  • BACKGROUND: Zebrafish have been used as a vertebrate model to study human cancers such as melanoma, rhabdomyosarcoma, liver cancer, and leukemia as well as for high-throughput screening of small molecules of therapeutic value. However, they are just emerging as a model for human brain tumors, which are among the most devastating and difficult to treat. In this study, we evaluated zebrafish as a brain tumor model by overexpressing a human version of oncogenic KRAS (KRAS[superscript G12V]). METHODS: Using zebrafish cytokeratin 5 (krt5) and glial fibrillary acidic protein (gfap) gene promoters, we activated Ras signaling in the zebrafish central nervous system (CNS) through transient and stable transgenic overexpression. Immunohistochemical analyses were performed to identify activated pathways in the resulting brain tumors. The effects of the MEK inhibitor U0126 on oncogenic KRAS were evaluated. RESULTS: We demonstrated that transient transgenic expression of KRAS[superscript G12V] in putative neural stem and/or progenitor cells induced brain tumorigenesis. When expressed under the control of the krt5 gene promoter, KRAS[superscript G12V] induced brain tumors in ventricular zones (VZ) at low frequency. The majority of other tumors were composed mostly of spindle and epithelioid cells, reminiscent of malignant peripheral nerve sheath tumors (MPNSTs). In contrast, when expressed under the control of the gfap gene promoter, KRAS[superscript G12V] induced brain tumors in both VZs and brain parenchyma at higher frequency. Immunohistochemical analyses indicated prominent activation of the canonical RAS-RAF-ERK pathway, variable activation of the mTOR pathway, but no activation of the PI3K-AKT pathway. In a krt5-derived stable and inducible transgenic line, expression of oncogenic KRAS resulted in skin hyperplasia, and the MEK inhibitor U0126 effectively suppressed this pro-proliferative effects. In a gfap-derived stable and inducible line, expression of oncogenic KRAS led to significantly increased mitotic index in the spinal cord. CONCLUSIONS: Our studies demonstrate that zebrafish could be explored to study cellular origins and molecular mechanisms of brain tumorigenesis and could also be used as a platform for studying human oncogene function and for discovering oncogenic RAS inhibitors.
  • Keywords: gfap, krt5, Oncogenic KRAS (KRAS[superscript G12V]), Zebrafish, Drug screening, Brain tumors
Resource Type
DOI
Date Available
Date Issued
Citation
  • Ju, B., Chen, W., Orr, B. A., Spitsbergen, J. M., Jia, S., Eden, C. J., ... & Taylor, M. R. (2015). Oncogenic KRAS promotes malignant brain tumors in zebrafish. Molecular Cancer, 14, 18. doi:10.1186/s12943-015-0288-2
Journal Title
Journal Volume
  • 14
Déclaration de droits
Funding Statement (additional comments about funding)
  • This research was supported by the St. Jude Children’s Research Hospital and ALSAC.
Publisher
Peer Reviewed
Language
Replaces

Des relations

Parents:

This work has no parents.

Articles

La vignette Titre Date de téléchargement Visibilité actes
file details SpitsbergenJanMicrobiologyOncogenicKRASPromotes.pdf 07/25/2017 Public
file details SpitsbergenJanMicrobiologyOncogenicKRASPromotes_AdditionalFiles.pdf 07/25/2017 Public